Diagnostic and prognostic impact of osteopontin expression in endometrial cancer

Han Byoul Cho; Eun Suk Kang; Young Tae Kim; Jae Hoon Kim

doi:10.1080/07357900802375738

Diagnostic and prognostic impact of osteopontin expression in endometrial cancer

Han Byoul Cho, Eun Suk Kang, Young Tae Kim, Jae Hoon Kim

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Article

12 Citations (Scopus)

Abstract

The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).

Original language	English
Pages (from-to)	313-323
Number of pages	11
Journal	Cancer Investigation
Volume	27
Issue number	3
DOIs	https://doi.org/10.1080/07357900802375738
Publication status	Published - 2009 Mar 1

Fingerprint

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Cite this

Cho, H. B., Kang, E. S., Kim, Y. T., & Kim, J. H. (2009). Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Investigation, 27(3), 313-323. https://doi.org/10.1080/07357900802375738

@article{c84eb71ebb4744bdaf30267102407b85,

title = "Diagnostic and prognostic impact of osteopontin expression in endometrial cancer",

abstract = "The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).",

author = "Cho, {Han Byoul} and Kang, {Eun Suk} and Kim, {Young Tae} and Kim, {Jae Hoon}",

year = "2009",

month = mar

day = "1",

doi = "10.1080/07357900802375738",

language = "English",

volume = "27",

pages = "313--323",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Diagnostic and prognostic impact of osteopontin expression in endometrial cancer

AU - Cho, Han Byoul

AU - Kang, Eun Suk

AU - Kim, Young Tae

AU - Kim, Jae Hoon

PY - 2009/3/1

Y1 - 2009/3/1

N2 - The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).

AB - The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).

UR - http://www.scopus.com/inward/record.url?scp=63349090034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63349090034&partnerID=8YFLogxK

U2 - 10.1080/07357900802375738

DO - 10.1080/07357900802375738

M3 - Article

C2 - 19194826

AN - SCOPUS:63349090034

VL - 27

SP - 313

EP - 323

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -

Access to Document

10.1080/07357900802375738